➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
Colorcon
Medtronic
Merck
McKesson

Last Updated: September 22, 2021

DrugPatentWatch Database Preview

Claims for Patent: 5,686,120

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

Summary for Patent: 5,686,120
Title: Pre-mRNA processing enhancer and method for intron-independent gene expression
Abstract:A chimeric RNA molecule comprising at least one pre-mRNA processing element is disclosed. A gene construct comprising a DNA sequence encoding at least one pre-mRNA processing enhancer is also disclosed. A method of enhancing cytoplasmic RNA accumulation is disclosed. This method comprises the step of inserting a DNA sequence encoding the RNA into the vector described and expressing the DNA sequence.
Inventor(s): Mertz; Janet E. (Madison, WI), Liu; Xuedong (Madison, WI)
Assignee: Wisconsin Alumni Research Foundation (Madison, WI)
Application Number:08/447,313
Patent Claims:1. A chimeric RNA molecule comprising a 5' untranslated region, a 3' untranslated region and a protein-coding sequence, wherein the 5' untranslated region or the 3' untranslated region of the RNA molecule comprises at least one pre-mRNA processing element not natively connected to the protein-coding sequence, wherein the pre-mRNA processing enhancer has a nucleotide sequence selected from the group consisting of SEQ ID NO:1, NO:11, and NO:12.

2. A gene construct comprising a DNA sequence encoding at least one pre-mRNA processing enhancer downstream from a promoter and upstream from a protein coding sequence, wherein the promoter is operably connected to the protein-coding sequence, wherein the pre-mRNA processing enhancer is not natively connected to the protein coding sequence and wherein the pre-mRNA processing enhancer increases the accumulation of the protein coding sequence at least two-fold without requiring intron excision and wherein a single pre-mRNA processing enhancer is localized to a nucleotide length of less than 300 nucleotides.

3. A chimeric RNA molecule comprising a 5' untranslated region, a 3' untranslated region and a protein-coding sequence, wherein the 5' untranslated region of the RNA molecule comprises at least one pre-mRNA processing element not natively connected to the protein-coding sequence and wherein the pre-mRNA processing enhancer is within the 5' untranslated region, additionally comprising a translation enhancer sequence upstream from the protein-coding sequence and downstream from the pre-mRNA processing enhancer.

4. A gene construct comprising a DNA sequence encoding at least one pre-mRNA processing enhancer, wherein said construct comprises a unique restriction endonuclease site downstream from said DNA sequence and wherein the restriction endonuclease site is part of a polylinker.

Details for Patent 5,686,120

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04 ⤷  Free Forever Trial Wisconsin Alumni Research Foundation (Madison, WI) 2039-02-26 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04 ⤷  Free Forever Trial Wisconsin Alumni Research Foundation (Madison, WI) 2039-02-26 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04 ⤷  Free Forever Trial Wisconsin Alumni Research Foundation (Madison, WI) 2039-02-26 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Medtronic
Mallinckrodt
Boehringer Ingelheim
AstraZeneca
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.